บุคลากรอาจารย์อาวุโส

รศ.ดร.ภญ. สุวัฒนา จุฬาวัฒนทล รศ.ดร.ภญ. สุวัฒนา จุฬาวัฒนทล suvatna.chu@mahidol.ac.th suvatna.chu@mahidol.ac.th อาจารย์ประจำภาควิชาเภสัชกรรม

2021

1. Educational program to improve hypertension knowledge by a community pharmacist in a rural district in Indonesia

   Wulandari UA, Kristina SA, Chindavijak B, Chulavatnatol S, Nathisuwan S*. JACCP journal of the american college of clinical pharmacy 2021; 4(6): 711-717.
   
   

2. Knowledge of stroke and medication adherence among patients with recurrent stroke or transient ischemic attack in Indonesia: a multi-center, cross-sectional study

   Widjaja KK, Chulavatnatol S, Suansanae T, Wibowo YI, Sani AF, Islamiyah WR, Nathisuwan S*. Int J Clin Pharm 2021; 43(3): 666-672.
   
   

3. Prescriber compliance to direct oral anticoagulant labels and impact on outcomes in Thailand

   Wattanaruengchai P, Nathisuwan S*, Rattanavipanon W, Chulavatnatol S, Kongwatcharapong J, Mitsuntisuk P, Chaiyasothi T, Kritsanapipat D, Phrommintikul A, Chaiyakunapruk N, Likittanasombat K, Lip GYH. British journal of clinical pharmacology 2021; 87(3): 1390-1400.
   
   

4. Real-world comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants vs. warfarin in a developing country

   Mitsuntisuk P, Nathisuwan S*, Junpanichjaroen A, Wongcharoen W, Phrommintikul A, Wattanaruengchai P, Rattanavipanon W, Chulavatnatol S, Chaiyakunapruk N, Likittanasombat K, Lip GYH. Clinical Pharmacology and Therapeutics 2021; 109(5): 1282-1292.
   
   

2020

1. Comparative in vitro activity of sitafloxacin against multidrug-resistant and carbapenem-resistant Acinetobacter baumannii clinical isolates in Thailand

   Paiboonvong T, Rodjun V, Houngsaitong J, Chomnawang M, Montakantikul P, Chulavatnatol S*. Pharmaceutical sciences asia 2020; 47(1): 37-42.
   
   

2. Genetic and clinical risk factors associated with phenytoin-induced cutaneous adverse drug reactions in Thai population

   Sukasem C, Sririttha S, Tempark T, Klaewsongkram J, Rerkpattanapipat T, Puangpetch A, Boongird A, Chulavatnatol S*. Pharmacoepidemiol drug saf 2020; 29(5): 565-574.
   
   

3. Knowledge of stroke and medication adherence among patients with recurrent stroke or transient ischemic attack in Indonesia: a multi‑center, cross‑sectional study

   Widjaja KK, Chulavatnatol S, Suansanae T, Wibowo YI, Sani AF, Islamiyah WR, Nathisuwan S International Journal of Clincal Pharmacy 2020 Oct 29. doi: 10.1007/s11096-020-01178-y
   
   

4. Prescriber compliance to direct oral anticoagulant labels and impact on outcomes in Thailand

   Wattanaruengchai P, Nathisuwan S, Rattanavipanon W, Chulavatnatol S, Kongwatcharapong J, Mitsuntisuk P, Chaiyasothi T, Kritsanapipat D, Phrommintikul A, Chaiyakunapruk N, Likittanasombat K, Lip GYH Br J Clin Pharmacol 2020 Aug 28. doi: 10.1111/bcp.14535
   
   

5. Real-world comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants vs. warfarin in a developing country

   Mitsuntisuk P, Nathisuwan S, Junpanichjaroen A, Wongcharoen W, Phrommintikul A, Wattanaruengchai P, Rattanavipanon W, Chulavatnatol S, Chaiyakunapruk N, Likittanasombat K, Lip GYH Clin Pharmacol Ther 2020 Oct 28. doi: 10.1002/cpt.2090
   
   

6. Relationship of anemia and clinical outcome in heart failure patients with preserved versus reduced ejection fraction in a rural area of Thailand

   Chairat K, Rattanavipanon W, Tanyasaensook K, Chindavijak B, Chulavatnatol S, Nathisuwan S*. Int J cardiol heart vasc 2020; 30: 100597.
   
   

2019

1. Incidence, risk factors, and outcomes of warfarin-associated major bleeding in Thai population

   Priksri W, Rattanavipanon W, Saejear W, Tanyasaensook K, Phrommintikul A, Chulavatnatol S, Nathisuwan S Pharmacoepidemiology and Drug Safety 2019;28:942-950
   
   

2. Prognostic value of serum procalcitonin level for the diagnosis of bacterial infections in critically-ill patients

   So-Ngern A, Leelasupasri S, Chulavatnatol S, Pummangura C, Bunupuradah P, Montakantikul P Infection and Chemotherapy 2019;51(3):263-273. doi: 10.3947/ic.2019.51.3.263
   
   

2018

1. Comparative performance of pharmacogenetics-based warfarin dosing algorithms derived from caucasian, asian, and mixed races in Thai population

   Chumnumwat S, Yi K, Lucksiri A, Nosoongnoen W, Chindavijak B, Chulavatnatol S, Sarapakdi A, Nathisuwan S*. Cardiovascular Therapeutics 2018; 36(2): e12315
   
   

2015

1. Safety Profile of Voriconazole in Thai patients: A Retrospective, Descriptive Study

   Montakarntikul P, Putthipokin K, Watcharananon SP, Chulavatnatol S*. Songklanagarind Medical Journal 2015; 33(3): 153-163.
   
   

2014

1. Adverse Drug Event of Hospitalized Patients from Multi-Hospitals in Thailand

   Tragulpiankit P, Yeesoonpan N, Ninsananda T, Chindavijak B, Chulavatnatol S, Chaikledkaew U, Uaviseswong T. Pharmacoepidemiology and drug safety 2014; 23: 289-289
   
   

2012

1. Adverse drug events in rheumatoid arthritis and osteoarthritis ambulatory patients

   Tragulpiankit P*, Chulavatnatol S, Rerkpattanapipat T, Janwityanujit S, Somjarit S, Sirikhedgon U. International Journal of Rheumatic Diseases 2012; 15(3): 315-321
   
   

2. Population pharmacokinetics of vancomycin in Thai patients

   Purwonugroho TA, Chulavatnatol S*, Preechagoon Y, Chindavijak B, Malathum K, Bunuparadah P. The Scientific World Journal 2012; 2012
   
   

2011

1. Measured versus estimated creatinine clearance in elderly patients

   Tragulpiankit P, Montakantikul P, Chulavatnatol S, Chansirikarnjana S, Thawinwang A. Journal of Applied Therapeutic Research 2011; 8(2): 43-51
   
   

2. Pharmacokinetics and clinical application of intravenous valproate in Thai epileptic children

   Visudtibhan A*, Bhudhisawadi K, Vaewpanich J, Chulavatnatol S, Kaojareon S. Brain Dev 2011; 33(3): 189-194.
   
   

2010

1. Bioequivalence of indinavir capsules in healthy volunteers

   Chulavatnatol S*, Malathum K, Kiertiburanakul S, Sripha K Lawanprasert P. Asian Biomed 2010; 4(1): 95-101.
   
   

2. Formulation development of morphine sulfate sustained-release tablets and its bioequivalence study in healthy Thai volunteers

   Preechagoon D*, Sumyai V, Chulavatnatol S, Kulvanich P, Tessiri T, Tontisirin K, Pongjanyakul T, Uchaipichat V, Aumpon S, Wongvipaporn C. AAPS PharmSciTech 2010; 11(3): 1449-1455.
   
   

2009

1. การพัฒนาวิธีวิเคราะห์มอร์ฟีนในพลาสมามนุษย์โดยการใช้เทคนิคโครมาโทกราฟีของเหลวสมรรถนะสูงร่วมกับเครื่องตรวจวัดแบบเคมีไฟฟ้าชนิดคูลอมเมตริก

   ธานี เทศศิริ, วิโรจน์ สุ่มใหญ่, สุวัฒนา จุฬาวัฒนทล, พจน์ กุลวานิช, ขนิษฐา ตันติศิรินทร์, ธเนศ พงศ์จรรยากุล, ศิริกุล อำพล, วีรวรรณ อุชายอภิชาติ, เดชพล ปรีชากุล วารสารเภสัชศาสตร์อีสาน 2552; 5(2): 123-130
   
   

2008

1. Prevalence and characteristics of adverse drug events in rheumatoid arthritis and osteoarthritis ambulatory patients at a large teaching hospital, Thailand.

   Limsuwan T, Tragulpiankit P, Chulavatnatol S, Janwityanujit S, Sirikhedgon U, Somjarit S. European Journal of Dermatology 2008;18:262-3.
   
   

2007

1. Adverse Drug Event of Rheumatoid Arthritis and Osteoarthritis Ambulatory Patients in a Large

   Tragulpiankit P, Chulavatnatol S, Limsuwan,T , Sirikhedgon U, Somjarit S Drug Safety 2007; 30(10): 950.
   
   

2006

1. Preliminary review of Thai pharmacists

   Tragulpiankit P, Chulavatnatol S. Drug Saf 2006;29:976.
   
   

2003

1. Pharmacokinetics of ofloxacin in drug-resistant tuberculosis.

   Chulavatnatol S*, Chindavijak B, Chierakul N, Klomsawat D. J Med Assoc Thailand 2003; 86:781-8
   
   

2002

1. Potential adverse drug interaction in prescriptions of patients with cardiovascular diseases.

   Chulavatnatol S, Tragulpiankit P, Ruengcharoenrung K, Janpraparn J, Aumklad P. Thai Journal of Hospital Pharmacy 2002;12(1):18-30.
   
   

2001

1. Intrapulmonary pharmacokinetics of ofloxacin in drug-resistant tuberculosis.

   Chierakul N, Klomsawat D, Chulavatnatol S, Chindavijak B. Int J Tuberc Lung Dis 2001; 5(3): 278-82
   
   

1999

1. Pharmacokinetics of levofloxacin in healthy Thai male volunteers.

   Chulavatnatol S, Chindavijak B, Vibhagool A, Wananukul W, Sriapha C, Sirisangtragul C. J Med Assoc Thailand 1999; 82 (11): 1127-35
   
   

1998

1. Biovailability of phenytoin sodium capsules available in Thailand. Part II: In vivo study.

   Suthisisang C, Payakachat N, Chulavatnatol S, Towanabut T. J Med Assoc Thailand 1998; 81 (1): 64-70
   
   

2. The period prevalence of catamenial epilepsy at Prasat Neurological Institute, Bangkok.

   Towanabut T, Chulavatnatol S, Suthisisang C, Wanakamanee U. J Med Assoc Thailand 1998;81(12):970-7
   
   

1994

1. Antagonism of sodium amoxycillin absorption in man following oral administration with glycyl-peptides.

   Chulavatnatol S, Charies B. Eur J Pharm Biopharm 1994; 40:374-8
   
   

2. Determination of dose-dependent absorption of amoxycillin from urinary excretion data in healthy subjects Br

   Chulavatnatol S, Charies B. J Clin Pharmacol 1994; 38:274-7
   
   

1993

1. High-performance liquid chromatographic determination of amoxycillin in urine using solid-pharse, ion-pair extraction and ultraviolet detection.

   Chulavatnatol S, Charles B. J Chromatogr 1993;615:91-6
   
   

2. Simple analysis of amoxycillin in plasma by high performance liquid chromatography with internal standardization and ultraviolet detection.

   Charless BG, Chulavatnatol S. Biomed Chromatogr 1993;7:204-7
   
   

---

หมายเหตุ: ชื่อที่ใช้ในการทำวิจัยของ รศ.ดร.ภญ. สุวัฒนา จุฬาวัฒนทล ได้แก่ สุวัฒนา จุฬาวัฒนทล ; Chulavatnatol S ;